Related Experiment Video
Updated: Mar 1, 2026

Breath Collection from Children for Disease Biomarker Discovery
Published on: February 14, 2019
Exhaled volatile substances mirror clinical conditions in pediatric chronic kidney disease
Juliane Obermeier1, Phillip Trefz1, Josephine Happ1
1Department of Anesthesiology and Intensive Care Medicine, Rostock Medical Breath Research Analytics and Technologies (ROMBAT), University Medicine Rostock, Rostock, Germany.
Insights
Analyzing exhaled breath profiles in children with chronic kidney disease (CKD) revealed distinct metabolic changes. These early breath biomarkers indicate metabolic adaptation occurs even in mild CKD stages, offering a non-invasive monitoring approach.
Area of Science:
- Biochemistry
- Pediatric Nephrology
- Analytical Chemistry
Background:
- Monitoring metabolic adaptation in pediatric chronic kidney disease (CKD) is challenging.
- Non-invasive breath analysis offers a promising avenue for pediatric patient monitoring.
- Limited data exists on exhaled breath profiles in children with CKD.
Purpose of the Study:
- To investigate exhaled volatile organic compound (VOC) profiles in pediatric CKD patients and kidney transplant recipients.
- To identify potential breath biomarkers for early detection of metabolic changes in pediatric CKD.
- To correlate breath profiles with CKD stage, underlying renal disease, and transplant status.
Main Methods:
- Quantitative analysis of exhaled breath profiles using proton-transfer-reaction time-of-flight mass spectrometry (PTR-ToF).
- Study included 116 pediatric subjects: 48 with mild-to-moderate CKD, 8 with kidney transplants (KTx), and 60 healthy controls.
- Analysis considered CKD stage, renal disease type (HUS, glomerular, etc.), and transplant status as classifiers.
Main Results:
- Distinct exhaled VOC patterns were observed between CKD/KTx patients and healthy children.
- Elevated levels of ammonia, ethanol, isoprene, pentanal, and heptanal, and lower methylamine were found in patients.
- Ammonia accumulation was detected in CKD stage 1; alterations in isoprene, pentanal, and heptanal appeared in stages 2-4.
Conclusions:
- Non-invasive breath testing can reveal early metabolic adaptations in pediatric CKD.
- Specific VOCs like ammonia, isoprene, pentanal, and heptanal may serve as early biomarkers for CKD progression.
- Breath analysis holds potential for understanding disease mechanisms and guiding clinical management in pediatric kidney disease.
Abstract:
Monitoring metabolic adaptation to chronic kidney disease (CKD) early in the time course of the disease is challenging. As a non-invasive technique, analysis of exhaled breath profiles is especially attractive in children. Up to now, no reports on breath profiles in this patient cohort are available. 116 pediatric subjects suffering from mild-to-moderate CKD (n = 48) or having a functional renal transplant KTx (n = 8) and healthy controls (n = 60) matched for age and sex were investigated. Non-invasive quantitative analysis of exhaled breath profiles by means of a highly sensitive online mass spectrometric technique (PTR-ToF) was used. CKD stage, the underlying renal disease (HUS; glomerular diseases; abnormalities of kidney and urinary tract or polycystic kidney disease) and the presence of a functional renal transplant were considered as classifiers. Exhaled volatile organic compound (VOC) patterns differed between CKD/ KTx patients and healthy children. Amounts of ammonia, ethanol, isoprene, pentanal and heptanal were higher in patients compared to healthy controls (556, 146, 70.5, 9.3, and 5.4 ppbV vs. 284, 82.4, 49.6, 5.30, and 2.78 ppbV). Methylamine concentrations were lower in the patient group (6.5 vs 10.1 ppbV). These concentration differences were most pronounced in HUS and kidney transplanted patients. When patients were grouped with respect to degree of renal failure these differences could still be detected. Ammonia accumulated already in CKD stage 1, whereas alterations of isoprene (linked to cholesterol metabolism), pentanal and heptanal (linked to oxidative stress) concentrations were detectable in the breath of patients with CKD stage 2 to 4. Only weak associations between serum creatinine and exhaled VOCs were noted. Non-invasive breath testing may help to understand basic mechanisms and metabolic adaptation accompanying progression of CKD. Our results support the current notion that metabolic adaptation occurs early during the time course of CKD.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management

